Advanced search
Publication Cover
Expert Review of Anticancer Therapy Volume 13, 2013 - Issue 11
Submit an article Journal homepage
162
Views
7
CrossRef citations to date
0
Altmetric
Theme: Brain & Neurologic Cancer - Reviews

Biology in prevention and treatment of brain metastases

Anna S BerghoffDepartment of Medicine I and Comprehensive Cancer Center CNS Unit (CCC-CNS), Medical University of Vienna, Währinger Gürtel 18–20, 1090 Vienna, Austria
&
Matthias PreusserDepartment of Medicine I and Comprehensive Cancer Center CNS Unit (CCC-CNS), Medical University of Vienna, Währinger Gürtel 18–20, 1090 Vienna, AustriaCorrespondence[email protected]
Pages 1339-1348 | Published online: 10 Jan 2014

References

  • Barnholtz-Sloan JS, Sloan AE, Davis FG et al. Incidence proportions of brain metastases in patients diagnosed (1973–2001) in the metropolitan detroit cancer surveillance system. J. Clin. Oncol. 22(14), 2865–2872 (2004).
  • Sperduto PW, Berkey B, Gaspar LE, Mehta M, Curran W. A new prognostic index and comparison to three other indices for patients with brain metastases: an analysis of 1,960 patients in the RTOG database. Int. J. Radiat. Oncol. Biol. Phys. 70(2), 510–551 (2008).
  • Sperduto PW, Kased N, Roberge D et al. Summary report on the graded prognostic assessment: an accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases. J. Clin. Oncol. 30(4), 419–425 (2012).
  • Soffietti R, Kocher M, Abacioglu UM et al. A European Organisation for Research and Treatment of Cancer phase III trial of adjuvant whole-brain radiotherapy versus observation in patients with one to three brain metastases from solid tumors after surgical resection or radiosurgery: quality-of-life results. J. Clin. Oncol. 31(1), 65–72 (2013).
  • Mehta MP, Paleologos NA, Mikkelsen T et al. The role of chemotherapy in the management of newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline. J. Neurooncol. 96(1), 71–83 (2010).
  • Soffietti R, Trevisan E, Ruda R. Targeted therapy in brain metastasis. Curr. opin. oncol. 24(6), 679–686 (2012).
  • Weller RO, Djuanda E, Yow HY, Carare RO. Lymphatic drainage of the brain and the pathophysiology of neurological disease. Acta Neuropathol. 117(1), 1–14 (2009).
  • Kim MY, Oskarsson T, Acharyya S et al. Tumor self-seeding by circulating cancer cells. Cell 139(7), 1315–1326 (2009).
  • Kienast Y, von Baumgarten L, Fuhrmann M et al. Real-time imaging reveals the single steps of brain metastasis formation. Nat. Med. 16(1), 116–122 (2010).
  • Pivot X, Semiglazov V, Zurawski B et al. CEREBEL (EGF111438): an open label randomised phase III study comparing the incidence of CNS metastases in patients with HER2+ metastatic breast cancer, treated with lapatinib plus capecitabine versus trastuzumab plus capecitabine. Presented at: ESMO. Vienna, Austria, 28 September–2 October, Abstract LBA 11 (2012).
  • Chao YL, Shepard CR, Wells A. Breast carcinoma cells re-express E-cadherin during mesenchymal to epithelial reverting transition. Mol. Cancer 9, 179 (2010).
  • Shabani HK, Kitange G, Tsunoda K et al. Immunohistochemical expression of E-cadherin in metastatic brain tumors. Brain Tumor Pathol. 20(1), 7–12 (2003).
  • Fujita N, Takagi S. The impact of Aggrus/podoplanin on platelet aggregation and tumour metastasis. J. Biochem. 152(5), 407–413 (2012).
  • Labelle M, Begum S, Hynes RO. Direct signaling between platelets and cancer cells induces an epithelial-mesenchymal-like transition and promotes metastasis. Cancer Cell 20(5), 576–590 (2011).
  • Labelle M, Hynes RO. The initial hours of metastasis: the importance of cooperative host-tumor cell interactions during hematogenous dissemination. Cancer Discov. 2(12), 1091–1099 (2012).
  • Rejniak KA. Investigating dynamical deformations of tumor cells in circulation: predictions from a theoretical model. Front. Oncol. 2, 111 (2012).
  • Goubran HA, Burnouf T, Radosevic M, El-Ekiaby M. The platelet-cancer loop. Eur. J. Intern. Med. 24(5), 393–400 (2013).
  • Preusser M, Capper D, Ilhan-Mutlu A et al. Brain metastases: pathobiology and emerging targeted therapies. Acta neuropathol. 123(2), 205–222 (2012).
  • Li B, Wang C, Zhang Y et al. Elevated PLGF contributes to small-cell lung cancer brain metastasis. Oncogene 32(24), 2952–2962 (2012).
  • Barnhill RL, Benson PJ, Lugassy C. Conspicuous angiotropism of malignant melanoma involving the brain: implications for extravascular migratory metastasis. Am. J. Dermatopathol. 31(2), 205–208 (2009).
  • Hung T, Morin J, Munday WR et al. Angiotropism in primary cutaneous melanoma with brain metastasis: a study of 20 cases. Am. J. Dermatopathol. 35(6), 650–654 (2013).
  • Berghoff A, Rajky O, Winkler F et al. Evaluation of invasion patterns and their correlation with integrin expression in alphavbeta brain metastases of solid cancers. J. Clin. Oncol. 30( Suppl.), Abstract 2059 (2013).
  • Friedl P, Alexander S. Cancer invasion and the microenvironment: plasticity and reciprocity. Cell 147(5), 992–1009 (2011).
  • Carbonell WS, Ansorge O, Sibson N, Muschel R. The vascular basement membrane as “soil” in brain metastasis. PLoS ONE 4(6), e5857 (2009).
  • Wu YJ, Muldoon LL, Gahramanov S et al. Targeting alphaV-integrins decreased metastasis and increased survival in a nude rat breast cancer brain metastasis model. J. Neurooncol. 110(1), 27–36 (2012).
  • Bonneh-Barkay D, Wiley CA. Brain extracellular matrix in neurodegeneration. Brain Pathol. 19(4), 573–585 (2009).
  • Marchetti D, Reiland J, Erwin B, Roy M. Inhibition of heparanase activity and heparanase-induced angiogenesis by suramin analogues. Int. J. Cancer 104(2), 167–174 (2003).
  • Tester AM, Waltham M, Oh SJ et al. Pro-matrix metalloproteinase-2 transfection increases orthotopic primary growth and experimental metastasis of MDA-MB-231 human breast cancer cells in nude mice. Cancer Res. 64(2), 652–658 (2004).
  • Berghoff AS, Spanberger T, Ilhan-Mutlu A et al. Preoperative diffusion-weighted imaging of single brain metastases correlates with patient survival times. PLoS ONE 8(2), e55464 (2013).
  • Xing F, Kobayashi A, Okuda H et al. Reactive astrocytes promote the metastatic growth of breast cancer stem-like cells by activating Notch signalling in brain. EMBO Mol. Med. 5(3), 384–396 (2013).
  • Lin Q, Balasubramanian K, Fan D et al. Reactive astrocytes protect melanoma cells from chemotherapy by sequestering intracellular calcium through gap junction communication channels. Neoplasia 12(9), 748–754 (2010).
  • Gril B, Palmieri D, Qian Y et al. Pazopanib inhibits the activation of PDGFRbeta-expressing astrocytes in the brain metastatic microenvironment of breast cancer cells. Am. J. Pathol. 182(6), 2368–2378 (2013).
  • Berghoff AS, Lassmann H, Preusser M, Hoftberger R. Characterization of the inflammatory response to solid cancer metastases in the human brain. Clin. Exp. Metastasis 30(1), 69–81 (2013).
  • Brantley EC, Guo L, Zhang C et al. Nitric oxide-mediated tumoricidal activity of murine microglial cells. Transl. Oncol. 3(6), 380–388 (2010).
  • Pukrop T, Dehghani F, Chuang HN et al. Microglia promote colonization of brain tissue by breast cancer cells in a Wnt-dependent way. Glia 58(12), 1477–1489 (2010).
  • Margolin K, Ernstoff MS, Hamid O et al. Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. Lancet Oncol. 13(5), 459–465 (2012).
  • Preusser M, Winkler F, Collette L et al. Trial design on prophylaxis and treatment of brain metastases: lessons learned from the EORTC Brain Metastases Strategic Meeting 2012. Eur. J. Cancer. 48(18), 3439–3447 (2012).
  • Neuwelt EA, Bauer B, Fahlke C et al. Engaging neuroscience to advance translational research in brain barrier biology. Nat. Rev. Neurosci. 12(3), 169–182 (2011).
  • Zhang RD, Price JE, Fujimaki T, Bucana CD, Fidler IJ. Differential permeability of the blood-brain barrier in experimental brain metastases produced by human neoplasms implanted into nude mice. Am. J. Pathol. 141(5), 1115–1124 (1992).
  • Demeule M, Regina A, Jodoin J et al. Drug transport to the brain: key roles for the efflux pump P-glycoprotein in the blood-brain barrier. Vascul. Pharmacol. 38(6), 339–348 (2002).
  • Eichler AF, Chung E, Kodack DP et al. The biology of brain metastases-translation to new therapies. Nat. Rev. Clin. Oncol. 8(6), 344–356 (2011).
  • Berger LA, Riesenberg H, Bokemeyer C, Atanackovic D. CNS metastases in non-small-cell lung cancer: current role of EGFR-TKI therapy and future perspectives. Lung Cancer 80(3), 242–248 (2013).
  • Welsh JW, Komaki R, Amini A. et al. Phase II trial of erlotinib plus concurrent whole-brain radiation therapy for patients with brain metastases from non-small-cell lung cancer. J. Clin. Oncol. 31(7), 895–902 (2013).
  • Bartolotti M, Franceschi E, Brandes AA. EGF receptor tyrosine kinase inhibitors in the treatment of brain metastases from non-small-cell lung cancer. Expert Rev. Anticancer Ther. 12(11), 1429–1435 (2012).
  • Burel-Vandenbos F, Ambrosetti D, Coutts M, Pedeutour F. EGFR mutation status in brain metastases of non-small cell lung carcinoma. J. Neurooncol. 111(1), 1–10 (2013).
  • Sekine A, Kato T, Hagiwara E et al. Metastatic brain tumors from non-small cell lung cancer with EGFR mutations: distinguishing influence of exon 19 deletion on radiographic features. Lung Cancer 77(1), 64–69 (2012).
  • Heon S, Yeap BY, Lindeman NI et al. The impact of initial gefitinib or erlotinib versus chemotherapy on central nervous system progression in advanced non-small cell lung cancer with EGFR mutations. Clin. Cancer Res. 18(16), 4406–4414 (2012).
  • Preusser M, Berghoff AS, Ilhan-Mutlu A et al. ALK gene translocations and amplifications in brain metastases of non-small cell lung cancer. Lung Cancer 80(3), 278–283 (2013).
  • Kwak EL, Bang YJ, Camidge DR et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N. Engl. J. Med. 363(18), 1693–1703 (2010).
  • Kaneda H, Okamoto I, and Nakagawa K. Rapid response of brain metastasis to crizotinib in a patient with alk rearrangement-positive non-small-cell lung cancer. J. Thorac. Oncol. 8(4), e32–e33 (2013).
  • Maillet D, Martel-Lafay I, Arpin D, Perol M. Ineffectiveness of crizotinib on brain metastases in two cases of lung adenocarcinoma with EML4-ALK rearrangement. J. Thorac. Oncol. 8(4), e30–e31 (2013).
  • Falk AT, Poudenx M, Otto J, Ghalloussi H, Barriere J. Adenocarcinoma of the lung with miliary brain and pulmonary metastases with echinoderm microtubule-associated protein like 4-anaplastic lymphoma kinase translocation treated with crizotinib: a case report. Lung Cancer 78(3), 282–284 (2012).
  • Oxnard GR, Binder A, Janne PA. New targetable oncogenes in non-small-cell lung cancer. J. Clin. Oncol. 31(8), 1097–1104 (2013).
  • Berghoff A, Bago-Horvath Z, De Vries C et al. Brain metastases free survival differs between breast cancer subtypes. Br. J. Cancer. 106(3), 440–446 (2012).
  • Bartsch R, Berghoff AS, Preusser M. Optimal management of brain metastases from breast cancer. Issues and considerations. CNS Drugs 27(2), 121–134 (2013).
  • Bachelot T, Romieu G, Campone M et al. Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study. Lancet Oncol. 14(1), 64–71 (2013).
  • Bartsch R, Preusser M. Primary systemic treatment of breast-cancer brain metastases. Lancet Oncol. 14(1), 8–9 (2013).
  • Gril B, Palmieri D, Qian Y et al. Pazopanib reveals a role for tumor cell B-Raf in the prevention of HER2+ breast cancer brain metastasis. Clin. Cancer Res. 17(1), 142–153 (2011).
  • Qian Y, Hua E, Bisht K et al. Inhibition of Polo-like kinase 1 prevents the growth of metastatic breast cancer cells in the brain. Clin. Exp. Metastasis. 28(8), 899–908 (2011).
  • Narayana A, Mathew M, Tam M et al. Vemurafenib and radiation therapy in melanoma brain metastases. J. Neurooncol. 113(3), 411–416 (2013).
  • Fonkem E, Uhlmann EJ, Floyd SR et al. Melanoma brain metastasis: overview of current management and emerging targeted therapies. Expert Rev. Neurother. 12(10), 1207–1215 (2012).
  • Long GV, Trefzer U, Davies MA et al. Dabrafenib in patients with Val600Glu or Val600Lys BRAF -mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. Lancet Oncol. 13(11), 1087–1095 (2012).
  • Falchook GS, Long GV, Kurzrock R et al. Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial. Lancet 379(9829), 1893–1901 (2012).
  • Rochet NM, Dronca RS, Kottschade LA et al. Melanoma brain metastases and vemurafenib: need for further investigation. Mayo Clin. Proc. 87(10), 976–981 (2012).
  • Mittapalli RK, Vaidhyanathan S, Sane R, Elmquist WF. Impact of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) on the brain distribution of a novel BRAF inhibitor: vemurafenib (PLX4032). J. Pharmacol. Exp. Ther. 342(1), 33–40 (2012).
  • Durmus S, Sparidans RW, Wagenaar E, Beijnen JH, Schinkel AH. Oral availability and brain penetration of the B-RAFV600E inhibitor vemurafenib can be enhanced by the P-GLYCOprotein (ABCB1) and breast cancer resistance protein (ABCG2) inhibitor elacridar. Mol. Pharm. 9(11), 3236–3245 (2012).
  • Ascierto PA, Simeone E, Giannarelli D, et al. Sequencing of BRAF inhibitors and ipilimumab in patients with metastatic melanoma: a possible algorithm for clinical use. J. Transl. Med. 10, 107 (2012).
  • Balakan O, Suner A, Yigiter R et al. Long-term survival in metastatic malignant melanoma: ipilimumab followed by vemurafenib in a patient with brain metastasis. Int. Med. 51(19), 2819–2823 (2012).
  • Cochran DC, Chan MD, Aklilu M et al. The effect of targeted agents on outcomes in patients with brain metastases from renal cell carcinoma treated with Gamma Knife surgery. J. Neurosurg. 116(5), 978–983 (2012).
  • Gore ME, Hariharan S, Porta C et al. Sunitinib in metastatic renal cell carcinoma patients with brain metastases. Cancer 117(3), 501–509 (2011).
  • Verma J, Jonasch E, Allen P, Tannir N, Mahajan A. Impact of tyrosine kinase inhibitors on the incidence of brain metastasis in metastatic renal cell carcinoma. Cancer 117(21), 4958–4965 (2011).

Websites

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.